Myasthenia gravis and Lambert-Eaton syndrome both cause unusual muscle weakness but in different ways. In addition to slight differences in symptoms, they produce different diagnostic test results ...

Lambert-Eaton myasthenic syndrome is a rare, autoimmune disorder that causes muscle weakness and fatigue. Learn more about how to treat LEMS.

For adult and pediatric patients 6 years of age and older weighing at least 45kg, the maximum daily dosage has been increased from 80mg to 100mg. The Food and Drug Administration (FDA) has ...

The FDA has granted approval to the first treatment for children with Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder.The drug, amifampridine (Ruzurgi), is approved for the ...

LEMS or Lambert Eaton Myasthenic Syndrome is also a condition of the neuromuscular end plate between the nerve and the muscle, but is a condition which causes gradual weakness in patient’s ...

Patients with nontumor Lambert-Eaton myasthenic syndrome had survival rates comparable to the general population, according to the results of an observational study conducted in the Netherlands.

The Food and Drug Administration (FDA) has approved Firdapse (amifampridine; Catalyst), a first-in-class treatment for adults with Lambert-Eaton myasthenic syndrome (LEMS).

The US Food and Drug Administration (FDA) has approved amifampridine (Firdapse, Catalyst Pharmaceuticals) 10-mg tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults ...

Catalyst Pharmaceuticals announces FIRDAPSE launch in Japan by DyDo Pharma for treating Lambert-Eaton myasthenic syndrome. Quiver AI Summary. Catalyst Pharmaceuticals, Inc. announced that its sub ...